Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
What is Lupus?
Systemic lupus erythematosus (SLE), which is more commonly referred to as lupus, is a disease that affects the immune system.
Patients with weakened immune systems — who are at high risk from covid-19 — say pharmacies are turning them away when they seek additional vaccine doses recommended by federal health officials.
A new paper in Rheumatology, published by Oxford University Press, indicates that researchers have developed a new, easier, and more accurate tool to measure the progress of lupus in patients.
New therapies for autoimmune rheumatic diseases (AIRDs) that are designed to better regulate lipid (fat) metabolism, could significantly reduce the harmful side-effects caused by conventional treatments, finds a new large-scale review led by UCL researchers.
A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.
Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery-;even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators.
The Lupus Research Alliance proudly announced today 11 research grant recipients in the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas from probing the development and progression of lupus to pointing to potential personalized therapies.
Researchers from Yale University School of Medicine found that vaccination during the first trimester does not produce congenital disabilities or size abnormalities.
University of Virginia School of Medicine researchers have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.
Researchers summarize the possible causes and routes of transmission of SARS-CoV-2 between humans and animals.
LMU immunologists have discovered how mutations in Roquin-1 trigger autoimmunity, but can also improve the body's fight against cancer cells.
A new study assessed the presence of autoantibodies against autoantigens associated with known autoimmune diseases in patients with COVID-19.
The study “Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19” was recently published on the preprint medRxiv* server.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that while hospitalized children with juvenile lupus have fewer adverse kidney outcomes overall, significant racial gaps for developing these complications persist and do not seem to be narrowing.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that heart rate monitoring is a feasible, accurate tool to check for heart rhythm abnormalities in the fetuses of pregnant women with anti-Ro/SSA antibodies.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups, and these worrying disparities may be driven by several socioeconomic factors.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that higher doses, longer duration of use, chronic kidney disease and Asian race could all be independent risk factors for retinopathy in people using hydroxychloroquine, an antimalarial drug commonly used to treat lupus, rheumatoid arthritis and other diseases.
Systemic lupus erythematosis (SLE) is an autoimmune disease in which the immune system targets tissues of the body, causing widespread inflammation and affecting multiple organs such as the kidney and the brain.
Systemic lupus erythematosus (SLE), commonly referred to as simply "lupus", is an autoimmune disorder where the body's immune system attacks healthy tissue.
Nine out of 10 patients with systemic lupus erythematosus -; the autoimmune disease also known as SLE -; are females.